Turning a Cancer Fuel Into an Immune Weapon

These modified cells showed improved infiltration and attack capabilities in

Scientists at Cold Spring Harbor Laboratory have discovered a way to reprogram a protein that drives cancer growth into a tool for fighting it. By activating the PPARD protein in immune cells, researchers enhanced the cells' ability to burn fat and target tumors. This breakthrough, reported in October 2026, suggests a new strategy for immunotherapy that could make the body's defenses more aggressive and metabolically efficient against cancer. The PPARD protein is known to promote tumor development in many cancers, but the study revealed its dual role when manipulated in immune cells. When activated, PPARD shifted immune cells into a state that increased fatty acid oxidation, giving them more energy and persistence in hostile tumor environments.

Health news

Ethical Decision-Making for Mental Health Professionals Using Large Language ModelsAI Discovers Hidden Health Data in Everyday CT ScansUltra‑Processed Food Drives Up National Health Costs by $360,000 a YearScientists engineer CAR-NK immune cells directly inside the body using mRNA nanoparticles

These modified cells showed improved infiltration and attack capabilities in preclinical models, effectively turning a cancer promoter into an anti-tumor force. How Metabolic Reprogramming Boosts Immune Attack The research team found that PPARD activation did not just increase energy production—it altered the immune cells' entire metabolic profile. By favoring fat burning over glycolysis, the cells became less reliant on sugar, a resource often depleted in tumors. This metabolic shift allowed them to function longer and resist exhaustion, a major limitation in current immunotherapies. Experiments showed that tumors grew significantly slower in models treated with PPARD-enhanced immune cells compared to controls. Can This Approach Work Across Different Cancer Types? While the study focused on specific cancer models, the underlying mechanism suggests broader potential.

Since PPARD is present in many immune cell types and tumors often create

Since PPARD is present in many immune cell types and tumors often create metabolically hostile environments, the strategy could apply to various cancers where immune cells struggle to persist. Researchers are now testing whether combining PPARD activation with existing checkpoint inhibitors improves outcomes. Early data indicate synergy, but human trials remain years away. Frequently Asked Questions What is PPARD and why is it important in cancer? PPARD is a protein that regulates metabolism and can promote tumor growth when active in cancer cells, but the study shows it can enhance anti-tumor activity when activated in immune cells. How does activating PPARD help immune cells fight cancer? It shifts their metabolism to burn fat for fuel, giving them more energy and resilience in the nutrient-poor tumor environment, improving their ability to attack and persist. Is this treatment ready for use in patients?

No, the findings are based on preclinical models; further research and clinical trials are needed before any human application can be considered.